

YICHANG HUMANWELL PHARMACEUTICAL CO., LTD.





Company Profile

- ◆ Founded in 1954, Yichang Humanwell Pharmaceutical Co., Ltd. Yichang Humanwell is a fully integrated healthcare solution provider in China.
- Headquartered at the center of China, Yichang City with 3 manufacturing sites.
- ◆ Yichang Humanwell is leading in several therapeutic areas, especially in anesthetics and pain management in China, and is one of the largest providers of anesthetics medicines in Asia. It accounts for 68% of the market share of narcotic drugs in 2018 in China, and its core products include injectables of Fentanyl, Sufentanil, Remifentanil and Hydromorphone. It also develops Extended Release Rx drugs and OTC monograph products.
- **♦** Yichang Humanwell is active in over **25** countries.
- ◆ Humanwell Healthcare Group, a publicly listed company on the Shanghai stock exchange, is the controlling shareholder of Yichang Humanwell. It ranks 11th among the top 100 Chinese pharmaceutical companies in 2018.
- ♦ Sinopharm Group Co., Ltd., the leading pharmaceutical wholesaler and distributor in China, ranking the 25th among the Fortune 500 Chinese companies (2018), holds 20% of Yichang Humanwell's stock shares.





Company Profile

Turnover (2018) 467 million USD

Total employee 4700+

Domestic Narcotics Market share 68%

Total asset **529 million USD**


Annual growth rate 25%+





GEOGRAPHICAL POSITION









Dongshan Site



Plant area: 38 acres

Products: Narcotic APIs and Finished

Dosages

Capacity:

- □ 600 million ampoules of small volume injection
- □ 20 million vials of lyophilized powder for injection
- ☐ 1200kg max per year for Fentanyl citrate dedicated production line
- □ 80kg max per year for Sufentail citrate dedicated production line.
- □ 250kg max per year for Remifentanil HCldedicated production line



Yuan' an Site



Plant area: 86 acres

Products: Drugs in National Essential Medicine List, and CMO service

Capacity:

- □ 5 billion tablets;
- □ 100 million bags of granules;
- □ 1.4 billion hard capsules;
- □ 200 million soft capsules;
- □ 8 million bottles of oral solution.

Certification:

National GMP 2010 version

MHRA GMP





Hua Yan Site



OSD Plant area: 115 acres

Products: Oral Solid Dosage Forms

Capacity:

☐ 5 billion tablets and capsules

Certification:

June 2016

First Pre-Approval Inspection by US FDA with **Zero**

Observation

January 2017

Second Pre- Approval Inspection by US FDA with Zero

Observation

March 2018

First On-Site Inspection by UK MHRA with No Critical or

Major Deficiencies

June 2018

Third Pre-Approval Inspection by US FDA with **Zero**

Observation





International Certification of the Quality Management

No.	Official Organization	Products	Manufacturing Workshop	Date of Obtainment
1	Ethiopia FDA	Fentanyl Citrate Injection	Small Volume Injection Plant	2013.09.12
2	Kenya MOH	Fentanyl Citrate Injection	Small Volume Injection Plant	2014.06.30
3	Korea MFDS	Remifentanyl Hydrochloride	API Plant	2016.04.19
4	EU EDQM	API (Fentanyl Citrate)	Narcotic API workshop	2016.10.11
5	Uganda	small-volume injection, Lyophilized powder injections	small-volume injection workshop, Lyophilization & Emulsion Plant	2017.08.11
6	USA FDA	Oral Metformin Hydrochloride Tablets 500mg, 850mg and 1000mg	Yichang Humanwell OSD Plant	2017.01.13
7	USA FDA	Oral Potassium chloride sustained-release tablets 8mEq (600mg) and 10Eq (750mg)	Yichang Humanwell OSD Plant	2017.03.08
8	UK MHRA	GMP Inspection(Tramadol Hydrochloride capsule 50mg)	Yichang Humanwell OSD Plant	2018.04.10
9	USA FDA	Oral Micron Hydrochloride sustained release capsule 7mg, 14mg, 21mg, 28mg	Yichang Humanwell OSD Plant	2018.06.25
10	Columbia	Fentanyl Citrate Injection; Remifentanil Hydrochloride for Injection	Small Volume Injection Plant; Lyophilization & Emulsion Plant	2019.03.01
11	UK MHRA	GMP Insepection(Paracetamol Tablets 500mg)	Oral Dosage Form Plant 1	2019.07.11



MAIN PRODUCTS

Fentanyl Citrate Injection Remifentanil
HCl For
Injection

Sufentanil Citrate Injection

Alfentanil HCL Injection

Flumazenil Injection

Midazolam Injection

Pethidine HCl Injection

Ropivacaine HCl Injection

Paracetamol & Tramadol HCl Tablets

Hydromorphone HCl Injection

Nalbuphine HCL Injection

Dexmedetomidine HCl injection






NEW DRUGS IN PIPELINE

	Product	Pre-clinical	Phase 1	Phase 2	Phase 3	
Fospropofol Disodium Lyophilized Powder Inj.						
R	emimazolam Injection					
E	mulsified Isoflurane Inj.					
O	xycodone HCL and Ibuprofen Tablet					
N	lidazolam Oral Solution					
Ib	ouprofen and Hydrocodone Bitartrate Tablet					
В	uprenorphine HCL and Naloxone HCL Sublingual Tablet					





BUSINESS DISTRIBUTION







DOMESTIC MARKET

Anesthesiology
dept,
Oncology dept,
Pain
Management
dept,
ICU and
Pharmaceutical
preparation
section etc.

- Products are used in more than 18,000 hospitals, in which 1280 hospitals with annual operational cases exceeding 5000
- 31branch offices in whole country
- Over 3000 staff across every corner of China

Products Coverage rate in Anesthesiology dept Top-class hospitals is 98.6%

Hospitals with annual operations exceeding 5000 is 98.8%







ACADEMIC ACTIVITIES





Actively participate in Academic activities. such as CSA(annual meeting of Chinese society of anesthesiology) OCAP (oriental congress of anesthesiology and preoperative medicine and etc.



MARKET ACTIVITIES



Signing ceremony with Indonesian pharmaceutical - China's narcotic drug technology exports to achieve new breakthrough





MARKET ACTIVITIES



In April 27th 2017, our company's featured product Rimifentanil have successsfuly come into the Philippines market, which is a new breakthrough of anaesthetic in the Philippine market.





MARKET ACTIVITIES



To provide product knowledge training for key customer





THANK YOU!

